A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 292 participants.
Also called NCT02390050
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 292 participants
- Sponsor
- Registry
-
NCT02390050
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Japan
- Registry status
- Completed
Technical summary
Registry record NCT02390050. Randomized; quadruple masking; primary purpose treatment. Start 2015-05-12 (actual); primary completion 2016-06-03 (actual). Results posted on 2021-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Bexagliflozin tablets
- Intervention (Drug)
- Bexagliflozin tablets, placebo
- Lead sponsor
- Theracos
Record details
- Record id
cardio:ct-nct02390050- Content hash
fa6f37535ebcc1a9d36bced48d34e3944bd16f74d016e7217c5fae3ffefa176c